Please assess the completion status of the following clinical trial:

Trial Title: Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Comply with all current Australian Schedule of Pharmaceutical Benefits S100 eligibility criteria.~* Able to give written informed consent and adhere to study visit schedule.~* South East Asian ethnicity (except for Caucasian Gt1/1b in comparator arm) i.e. born in Vietnam, Cambodia, Laos, Thailand, Hong Kong, and China or have both parents born in these countries.~* Genotype 1, 1a, 1b, 6, 6a, 6b, 7, 8, or 9, as classified by INNO-LiPA assay.~* Hemoglobin \>=120 g/L (females), \>=130 g/L (males).~* Platelet count \>=100 x 10\^9/L.~* Neutrophil count \>=1.5 x 10\^9/L.~* Negative pregnancy test for females.~* Thyroid stimulating hormone (TSH) within normal limits.~Exclusion Criteria:~* Participation in any other investigational drug program within 30 days of the Screening Visit.~* Human immunodeficiency virus (HIV) antibody positive or hepatitis B surface antigen (HBsAg) positive.~* Genotype 2, 3, 4, or 5, as classified by INNO-LiPA assay.~* Non South East Asian ethnicity (unless recruited to Caucasian GT1 comparator arm).~* Evidence of liver disease due to other disorders (e.g., hemachromatosis, Wilson's disease).~* Ongoing drug or alcohol abuse which in the opinion of the investigator would jeopardize the patient's ability to comply with study requirements.~* Inability to comply with study requirements for other reasons.~* Decompensated cirrhosis (Ascites, history of encephalopathy or bleeding varices, serum albumin \<35 g/L, prothrombin time (PT) prolonged by greater than 3 sec).~* Present or prior history of severe psychiatric disease requiring hospitalization or medication.~* History of severe seizure disorder.~* History of autoimmune disorders (e.g., rheumatoid arthritis, inflammatory bowel disease, immune thrombocytopenic purpura, systemic lupus erythematosus, or other mixed connective tissue disease, psoriasis, optic neuritis).~* Poorly controlled thyroid disease.~* Creatinine clearance \<50 mL/min.~* Severe cardiovascular disease.~* Hepatocellular cancer.~* Clinically significant ophthalmologic disorders.~* Hemoglobinopathies (e.g., thalassemia, sickle-cell anemia).~* Treatment or recent treatment with immunosuppressive agents (excluding short-term corticosteroid withdrawal), and immunosuppressed transplant recipients scheme.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genotype 1 SEA PEG-IFN/RIB 48 w (Type: ACTIVE_COMPARATOR): Genotype 1 hepatitis C virus (HCV)-infected Southeastern Asian (SEA) subjects treated for up to 48 weeks with PEG-Intron (peginterferon alfa-2b; PEG-IFN) REDIPEN and REBETOL (ribavirin; RIB) combination therapy
- Genotype 1 Caucasian PEG-IFN/RIB 48 w (Type: ACTIVE_COMPARATOR): Genotype 1 HCV-infected Caucasian subjects treated for up to 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
- Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 24 w (Type: EXPERIMENTAL): Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 24 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
- Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 48 w (Type: ACTIVE_COMPARATOR): Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).